OncoSwab Secures $3M Seed Funding to Revolutionize Early Lung Cancer Detection Worldwide

We are thrilled to announce that OncoSwab has successfully raised $3,000,000 in our latest funding round, marking a pivotal milestone in our mission to revolutionize lung cancer detection. With 75% of lung cancer cases currently detected too late for effective treatment, OncoSwab is on a critical quest to change this narrative by making early detection accessible to all. Our innovative, non-invasive, and easy-to-use test is designed to identify lung cancer in its earliest stages, potentially saving countless lives worldwide. This fresh injection of capital will accelerate our proof-of-concept trial, a collaborative effort with renowned hospitals and leading lung cancer experts across the United States and Europe, ensuring that our technology meets rigorous global standards. Founded by visionary scientists, OncoSwab operates at the dynamic cross-section of cutting-edge science and compassionate care, with dual hubs in San Francisco, California, and Corroux, Switzerland. Our journey has been buoyed by the support of esteemed partners such as the Health Wildcatters Accelerator, Swiss Government’s DayOne Tech, and several pre-seed investors who share our commitment to transforming patient outcomes. With the new funding, we will further refine our testing technology, expand our clinical collaborations, and scale our operational capabilities to reach a broader population. As we advance our clinical trials, we remain dedicated to our core mission of early cancer detection and to laying the groundwork for a future where lung cancer is caught in its infancy, giving patients a fighting chance at recovery. We invite the global healthcare community and investors to join us in this vital endeavor that promises to reshape cancer diagnostics.